InstrumentpanelPortföljerBevakningslistaGemenskapUpptäckSkärm
NOT FOR DISTRIBUTION

Covista Inc.

NYSE:CVSA Aktierapport

Börsvärde: US$4.3b

  • Översikt över företaget
    • Värdering
    • Framtida tillväxt
    • Tidigare resultat
    • Finansiell hälsa
    • Utdelning
  • Förvaltning
  • Ägarskap
  • Övrig information
  • Aktiegemenskap

Covista Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Steve Beard

Verkställande direktör

US$17.2m

Total ersättning

VD-lön i procent5.80%
Anställning som VD5yrs
Ägande av VD1.3%
Ledningens genomsnittliga anställningstid4.4yrs
Styrelsens genomsnittliga mandatperiod6.4yrs

Senaste uppdateringar av ledningen

Recent updates

User avatar
Uppdatering av berättelse • Aug 11

CVSA: Leadership Expansion And Healthcare Education Demand Will Drive Future Upside

Covista's analyst price target has shifted from $153.25 to $159.50, with analysts pointing to the recent fiscal Q4 results and their view that demand for healthcare professionals will continue to outpace supply as key supports for the updated valuation inputs. What’s in the News for Covista Covista expanded its leadership structure with an enlarged role for Scott Liles, who now leads corporate strategy and a new Performance Acceleration Office while continuing as President of the Medical and Veterinary segment.
User avatar
Uppdatering av berättelse • Jun 26

CVSA: Student Enrollment Momentum And Campus Expansion Will Support Future Upside

The analyst price target for Covista has increased from $130 to $140, with analysts citing updated assumptions on revenue growth, profit margins, and future P/E as the key reasons for the change. What’s in the News for Covista Covista raised its fiscal 2026 revenue guidance to a range of approximately US$1.93b to US$1.945b, compared with the prior range of US$1.9b to US$1.94b, with guidance implying about 8% to 9% year-over-year growth.
Seeking Alpha • Jun 03

Covista: Healthcare Education Growth At A Fair Price

Summary Covista (CVSA) is rated Hold, reflecting strong healthcare education positioning but a valuation that prices in much of its growth story. CVSA's enrollment growth, AI-enabled offerings, and robust cash flow support its strategic pivot, yet it trades near peer medians on key valuation multiples. Regulatory risks tied to Title IV funding and ongoing lawsuits warrant a risk premium, tempering the case for aggressive buying at current levels. Peers like PRDO offer lower multiples and stronger cash conversion, while LOPE commands a premium for a cleaner balance sheet and superior cash generation. Read the full article on Seeking Alpha
User avatar
Ny berättelse • Apr 22

Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential

Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?
User avatar
Ny berättelse • Apr 08

Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis

Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
User avatar
Ny berättelse • Mar 24

Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes

Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?
Analysartikel • Sep 27

With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysartikel • Aug 07

Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet

NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...
Analysartikel • Jul 07

An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued

Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • May 13

There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump

Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...
Analysartikel • May 07

If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysartikel • Apr 24

Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysartikel • Mar 25

Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate

Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • Mar 11

Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price

With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...
Analysartikel • Feb 24

Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?

Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...
Seeking Alpha • Feb 21

Adtalem Global Education: Surging On Registered Nurse Shortage

Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking Alpha
Analysartikel • Jan 21

With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysartikel • Dec 19

These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Dec 17

Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks

Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking Alpha
Analysartikel • Nov 26

Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up

Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...
Analysartikel • Oct 31

Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?

Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...
Analysartikel • Oct 16

Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Seeking Alpha • Oct 04

Adtalem Global Education Faces Problems But Is Growing Steadily

Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking Alpha
Analysartikel • Sep 16

Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysartikel • Aug 29

Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings

With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...
Analysartikel • Aug 14

We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative

Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...

Analys av ersättningar till VD

Hur har Steve Beard:s ersättning förändrats jämfört med Covista:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2026n/an/a

US$267m

Mar 31 2026n/an/a

US$250m

Dec 31 2025n/an/a

US$254m

Sep 30 2025n/an/a

US$247m

Jun 30 2025US$17mUS$1m

US$233m

Mar 31 2025n/an/a

US$229m

Dec 31 2024n/an/a

US$204m

Sep 30 2024n/an/a

US$172m

Jun 30 2024US$14mUS$987k

US$138m

Mar 31 2024n/an/a

US$111m

Dec 31 2023n/an/a

US$122m

Sep 30 2023n/an/a

US$108m

Jun 30 2023US$8mUS$950k

US$102m

Mar 31 2023n/an/a

US$79m

Dec 31 2022n/an/a

US$35m

Sep 30 2022n/an/a

US$47m

Jun 30 2022US$9mUS$828k

-US$36m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021n/an/a

-US$15m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021US$3mUS$600k

US$63m

Mar 31 2021n/an/a

US$139m

Dec 31 2020n/an/a

US$269m

Sep 30 2020n/an/a

US$246m

Jun 30 2020US$2mUS$598k

US$220m

Ersättning vs marknad: Steve s total kompensation ($USD 17.24M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 6.99M ).

Ersättning vs inkomst: Ersättningen för Steve har ökat med mer än 20 % det senaste året.


VD OCH KONCERNCHEF

Steve Beard (55 yo)

5yrs
Anställning
US$17,244,988
Kompensation

Mr. Stephen W. Beard, also known as Steve, J.D., serves as an Independent Director at Planet Fitness, Inc. since February 9, 2026. He served as Chief Operating Officer at Adtalem Global Education Inc. sinc...


Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Stephen Beard
CEO & Chairman5yrsUS$17.24m1.28%
$ 54.5m
Robert Phelan
Senior VP & CFO5.4yrsUS$2.02m0.15%
$ 6.2m
Douglas Beck
Senior VP of Institutional Support Services5.3yrsUS$1.65m0.087%
$ 3.7m
Michael Betz
Chief Growth & Innovation Officer and President of Walden University4.3yrsUS$2.59m0.093%
$ 3.9m
Scott Liles
Chief Strategy & Performance Officer and President of Medical and Veterinary2.4yrsUS$1.62m0.022%
$ 925.7k
Manjunath Gangadharan
VP & Chief Accounting Officer4.4yrsinga uppgifter0.010%
$ 444.5k
Jeremy Cohen
Vice President of Investor Relationsno datainga uppgifteringa uppgifter
Sara Hill
Senior VP & Chief Human Resources Officer2yrsinga uppgifter0.0083%
$ 351.7k
Megan Noel
Senior VP & Chief Corporate Affairs Officer1.3yrsinga uppgifteringa uppgifter
Amelia Manning
President of Chamberlain Universityless than a yearinga uppgifteringa uppgifter
Karen Cox
President of Chamberlain University8.1yrsUS$1.14m0.083%
$ 3.5m
Maureen Resac
Vice President of Treasury & Risk Managementno datainga uppgifteringa uppgifter
4.4yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder

Erfaren ledning: CVSA s ledningsgrupp anses vara erfaren ( 4.4 års genomsnittlig anställningstid).


Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Stephen Beard
CEO & Chairman5yrsUS$17.24m1.28%
$ 54.5m
William Burke
Independent Director9.7yrsUS$250.17k0.026%
$ 1.1m
Michael Malafronte
Lead Independent Director10.3yrsUS$251.42k0.40%
$ 17.0m
Kenneth Phelan
Independent Director6.4yrsUS$225.17k0.054%
$ 2.3m
Donna Hrinak
Independent Director7.9yrsUS$237.67k0.020%
$ 847.3k
Lisa Wardell
Director17.8yrsUS$273.17k0.13%
$ 5.4m
Sharon O'Keefe
Independent Director6.4yrsUS$237.67k0.040%
$ 1.7m
Emily Chiu
Independent Directorless than a yearinga uppgifteringa uppgifter
Betty Vandenbosch
Independent Director2.7yrsUS$225.17k0.0034%
$ 142.6k
Georgette Kiser
Independent Director8.3yrsUS$237.67k0.047%
$ 2.0m
William Krehbiel
Independent Director4.3yrsUS$225.17k0.044%
$ 1.9m
Leslie Storms
Independent Directorless than a yearinga uppgifteringa uppgifter
6.4yrs
Genomsnittlig anställningstid
58yo
Genomsnittlig ålder

Erfaren styrelse: CVSA s styrelse anses vara erfaren ( 6.4 års genomsnittlig mandatperiod).


Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/09/14 09:33
Aktiekurs vid dagens slut2026/09/14 00:00
Intäkter2026/06/30
Årlig intjäning2026/06/30

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
  • SEC Form 10-K
  • SEC Form 10-Q
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
  • Rapporter från analytiker
  • Blue Matrix
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
  • ICE Marknadsdata
  • SEC Form S-1
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
  • SEC Formulär 4
  • SEC Formulär 13D
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
  • SEC Form 10-K
  • SEC Form DEF 14A
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden
  • SEC Formulär 8-K

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Covista Inc. bevakas av 24 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Gary BisbeeBarclays
Gary PrestopinoBarrington Research Associates, Inc.
Alexander ParisBarrington Research Associates, Inc.

Ta bättre investeringsbeslut var som helst

Skanna för att ladda ner
Öppna App StoreÖppna Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Visa datakällor
Marknader
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investeringsidéer
  • Undervärderade bolag
  • Starka utdelningar
  • Insiderköp
  • Kärnenergi
  • Autonoma fordon
  • Artificiell intelligens
  • Krypto och blockkedja
  • Cybersäkerhet
  • Fler idéer
Lager Gemenskaperna
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Funktioner och verktyg
  • Portföljspårning
  • Aktieskärm och varningar
  • Berättelser & rättvisa värden
  • Kalkylator för utdelning
Nyheter & Upptäckter
  • Senaste lagernyheter
  • Global Market Insights
  • Foxhole-forumet
  • Investeringsidéer
  • Gemenskapens berättelser
  • Vad är nytt
Simply Wall St
  • Planer och priser
  • Annonsering
  • Om oss
  • Kontakta oss
  • Karriär
  • Hjälpcenter
  • Lär dig investera i aktier
  • Affiliate-program
  • Affärer & företag
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Villkor och anvisningar
  • Integritetspolicy
  • AI-villkor
  • Guide för finansiella tjänster